CTC-501

CTC-501 is a fixed-dose combination of pramipexole immediate-release plus ondansetron being developed by Chase Therapeutics Corporation as adjunctive therapy for major depressive disorder (MDD). The idea is mechanically simple: pramipexole, the dopamine D2/D3 agonist approved for Parkinson's disease and restless legs syndrome, has shown antidepressant activity in small randomized trials but causes nausea that caps tolerable dosing [1][11]. Ondansetron, the 5-HT3 antagonist sold for decades against chemotherapy-induced nausea, blocks that side effect. Combine them and the bet is that pramipexole can be pushed higher without losing patients to vomiting. The program is anchored on NCT03642964, a Phase 2a, placebo-controlled, single-blind tolerability study in up to 24 patients with MDD that was registered in August 2018 and is currently listed as active and not recruiting [2]. Eight years on a 24-patient tolerability study is the single loudest signal in this file. Both components are individually generic, so the commercial story rests entirely on whether the combination shows a differentiated efficacy signal in MDD adjunctive use, where aripiprazole, brexpiprazole, cariprazine, esketamine, and Auvelity already compete [3][4][12]. This is early, small, and sponsor-funded by a private company without disclosed clinical pipeline depth. The science is rational, but Phase 2a tolerability data will not by itself move the needle commercially.

Both individual components of CTC-501 are long-approved and generic. Pramipexole (Mirapex) was first approved in 1997 for Parkinson's disease and later for restless legs syndrome; ondansetron (Zofran) was first approved in 1991 for nausea and vomiting [5][6]. CTC-501 itself, as a fixed-dose combination for MDD, is investigational. NCT03642964 is registered as Phase 2a with Chase Therapeutics Corporation as sponsor, enrollment target 24, status active not recruiting [2]. The trial was registered in August 2018 and has been in active or active-not-recruiting status for approximately 8 years without results posted to ClinicalTrials.gov, which is unusually long for a 24-patient tolerability study. This duration raises questions about sponsor capacity, patient recruitment, or program prioritization that Chase has not publicly addressed. The primary endpoint is determination of the maximum tolerated dose of pramipexole when co-administered with ondansetron, signaling foundational dose-finding rather than a powered efficacy study. No FDA breakthrough therapy, fast track, orphan drug, or accelerated approval designations have been publicly disclosed for the program. No partnership, financing, or out-licensing announcements have surfaced from Chase Therapeutics around this asset that can be verified in public filings. A 505(b)(2) regulatory path is plausible and would let Chase use prior safety and pharmacology data on both molecules; the 505(b)(2) pathway lets a sponsor file a new drug application that relies partly on existing safety and efficacy data from previously approved drugs, reducing the cost and time of a full data package. The company has not publicly committed to that strategy. Expected readout timing is not disclosed. Chase Therapeutics remains a privately held, single-asset specialty company; no public corporate information beyond the NCT registration and the trial sponsor record could be verified for this writeup, which is itself a flag for evaluating execution credibility.

Depression is not just a serotonin problem. Many patients with treatment-resistant depression have prominent anhedonia, the loss of the ability to feel pleasure, which most SSRIs do not fix well. Anhedonia tracks more closely with dopamine signaling in reward circuits than with serotonin alone. Pramipexole binds and activates dopamine D2 and D3 receptors, with roughly 7-fold higher affinity for D3 over D2 in cloned receptor assays. D3 receptors are preferentially expressed in mesolimbic regions, including nucleus accumbens and ventral striatum, that are tied to motivation and reward, while D2 receptors dominate dorsal striatum and pituitary [7]. The D3 preference is the differentiation argument versus approved adjunctive antipsychotics like aripiprazole and cariprazine, which are predominantly D2 partial agonists; if dopamine reward-circuit modulation is what helps anhedonic depression, a D3-preferring full agonist plausibly engages that circuitry more directly. Pramipexole's antidepressant signal has small-scale RCT support: Goldberg et al. (Am J Psychiatry 2004) showed efficacy versus placebo in treatment-resistant bipolar depression [11], and Corrigan et al. (2000) reported antidepressant effects versus placebo in unipolar MDD [13]. The Cusin et al. open-label augmentation study in treatment-resistant unipolar depression added a supportive but lower-rigor data point [1]. Across these trials, effect sizes in unipolar MDD are inconsistent and samples are too small to establish a reliable estimate. A meaningful share of patients also drop out from nausea before reaching effective doses [1]. The nausea is mediated through 5-HT3 receptors in the gut and in the area postrema, a region of the brainstem that acts as the brain's vomiting control center and sits outside the blood-brain barrier. Ondansetron blocks those receptors. The combination logic is to remove the dose-limiting toxicity so the active drug can reach therapeutic levels. This parallels other 'active agent plus tolerability enabler' combinations, though unlike carbidopa/levodopa, where carbidopa blocks peripheral DOPA decarboxylase and thereby both reduces side effects and increases CNS levodopa exposure, ondansetron acts purely on the nausea signal and does not affect pramipexole's bioavailability or CNS penetration. The broader dopamine hypothesis of depression has support but is less mature than the monoamine framework. Validation comes from approved adjuncts: aripiprazole and cariprazine, both partial D2/D3 agonists, demonstrate that pushing on dopamine signaling helps in MDD [3][4]. CTC-501 takes a different angle, a full D3-preferring agonist plus an antiemetic chaperone.

NCT03642964 is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder, sponsored by Chase Therapeutics Corporation, registered in August 2018 [2]. The primary endpoint is tolerability, specifically determination of the maximum tolerated dose of pramipexole co-administered with ondansetron. The trial is listed as active, not recruiting, and no results have been posted to ClinicalTrials.gov as of June 2026. Approximately eight years on a 24-patient tolerability study, without a posted readout, is anomalous and should be read as a material execution flag rather than a routine status. Several design features are also worth flagging. Twenty-four patients is small even for a Phase 2a and means any efficacy readout will be exploratory and noisy. Single-blind designs allow investigator awareness of treatment assignment, which introduces bias in subjective outcomes like the Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating Scale (HAM-D), the two standard clinician-rated depression scales used as efficacy endpoints in MDD trials. Framing the trial around MTD finding rather than a powered efficacy comparison is appropriate for an early combination program, but it limits the read-through to a larger study. There is no head-to-head comparator against an approved adjunctive antipsychotic like aripiprazole. Without that benchmark, a positive absolute effect size will still leave open the question of differentiation in a crowded adjunctive market. The natural next step is a larger, double-blind, randomized Phase 2b sized to detect a clinically meaningful change versus placebo, ideally with anhedonia-specific endpoints layered onto MADRS, but Chase has not publicly disclosed a protocol or timeline for that next study.

The model estimates a 4% chance this drug is eventually approved. It starts from a historical base rate of about 24% for Phase 2 drugs in this area, then adjusts that number using ten facts about the trial and sponsor. The estimate is pulled down mainly by the sponsor's weak approval record, limited earlier-phase results, smaller-than-typical enrollment, and a randomized trial design. The remaining factors fall near average for this stage, so they do not shift the estimate much in either direction.

Efficacy risk is the biggest one. Pramipexole RCT data in depression is positive but small: Goldberg 2004 in bipolar depression and Corrigan 2000 in unipolar MDD both showed signals versus placebo, but effect sizes in unipolar MDD are inconsistent and samples are too small to support a reliable point estimate [1][11][13]. If the underlying single-agent effect is modest, ondansetron cannot manufacture efficacy where none exists. The MDD adjunctive market expects effect sizes meaningful enough to justify side-effect burden, and the bar is set by approved competitors with billions of patient-exposure years. Safety risk is non-trivial. Pramipexole carries a class warning for impulse control disorders including pathological gambling, compulsive shopping, hypersexuality, and binge eating, which have driven labeling action in Parkinson's [9]. Sudden-onset somnolence and sleep attacks are also class concerns. Whether these emerge at MDD-relevant doses is an open question that the Phase 2a is too small to settle. Ondansetron at high doses prolongs the QT interval, a finding that prompted FDA dose restriction in 2012 [10]. Execution risk is acute. NCT03642964 has been active for roughly eight years without a posted readout on a 24-patient tolerability study, and Chase Therapeutics is a privately held company with no broader clinical pipeline publicly disclosed. A registrational Phase 3 in MDD typically costs 80 to 150 million dollars and demands sites with depression expertise; running that without a strategic partner is a significant lift, and the trial-duration record does not build confidence that the sponsor can move at scale. Commercial risk: even with approval, payers will compare against generic aripiprazole, generic quetiapine, and brand brexpiprazole (Rexulti), which was approved in 2015 for adjunctive MDD and remains a branded competitor priced at a multiple of generic options [12]. A branded combination of two generic ingredients needs a clearly differentiated label, plausibly anchored on an anhedonia-specific benefit, to defend a premium price.

Worth tracking, quietly, but with a sharper expiration date than the typical watch item. The mechanism is rational, both components are well-characterized, the D3-preferring profile gives a plausible differentiation angle versus approved D2 partial agonists, and the dopamine-plus-antiemetic combination logic is sound enough that it deserves a Phase 2b. But the asset is at a stage where the meaningful readout is one trial away and the existing trial has been sitting open for eight years. The Phase 2a is a 24-patient tolerability study, so any MADRS or HAM-D numbers will be exploratory at best. The specific data point that would convert CTC-501 from noise to signal is a placebo-controlled, double-blind Phase 2b showing depression rating-scale improvement at or above the levels approved adjuncts deliver, with a clean anhedonia signal that creates a differentiation story. Without that, the program risks landing as another modest entrant in a market that already has cheap generic and branded options. Concrete watch items, with a clock: (1) NCT03642964 results posted to ClinicalTrials.gov, (2) a Phase 2b protocol registered, or (3) a disclosed partnership or financing event that would credibly fund the next study. If none of the three occurs by Q2 2027, roughly nine years past trial registration, the program should be downgraded from watch to inactive and the page footnoted as such. Either an interim corporate update or a results post from Chase Therapeutics before then resets the clock and re-opens the call.